Carrizo Oil & Gas Inc., up $1.99 at $28.15. Shares of the energy company rose after the company boosted its oil production guidance for the second quarter.

Shares of drug developer Synergy Pharmaceuticals Inc. traded higher after a Citi Investment Research analyst started covering the stock with a "Buy" rating based on the company's constipation drug candidate plecanatide.

NEW YORK, May 31, 2013 -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced that its President and CEO, Gary S. Jacob, Ph.

NEW YORK, June 3, 2013 -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced a change in the Company's presentation time at the 2013 Jefferies Global Healthcare ...

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares declined 4.43% to $4.96. The company on May 21 presented positive safety and efficacy results from its large multicenter trial of plecanatide in patients with chronic idiopathic constipation (CIC) at ...

NEW YORK, May 30, May 30, 2013 (GLOBE NEWSWIRE via COMTEX) -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) , a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has been upgraded to the MSCI ...

Shares of drug developer Synergy Pharmaceuticals Inc. traded higher Monday after a Citi Investment Research analyst started covering the stock with a "Buy" rating based on the company's constipation drug candidate plecanatide.

loading. Synergy Pharmaceuticals Inc. ( SGYP ) recently announced positive results from a multicenter trial which evaluated its pipeline candidate plecanatide for treating patients suffering from chronic idiopathic constipation (CIC).

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (NASDAQ: SGYP) disorders and diseases.

Shares of drug developer Synergy Pharmaceuticals Inc. rose after its chairman disclosed that he'd bought more of the company's stock.